Endocrine · Nov 16, 2026

A comparative analysis of the safety and tolerability of oral small-molecule versus injectable peptide GLP-1 receptor agonists

By Habib MA, Sulieman AK, Albarq Z et al.

Purpose To compare the safety and tolerability profiles of oral small-molecule glucagon-like peptide-1 receptor agonists (GLP-1RAs) against established injectable peptide GLP-1RAs, with emphasis on orforglipron, the most clinically advanced class member. Methods This narrative review synthesises receptor pharmacology, Phase 3 clinical trial data, network meta-analyses, and regulatory prescribing-information documents for orforglipron; early-phase data for GSBR-1290 and CT-996 are considered separately as hypothesis-generating only. Results Orforglipron occupies a non-canonical orthosteric pocket and elicits Gs-protein-biased signalling; as a chemically stable small molecule, it also eliminates cold-chain dependence and parenteral administration burden. Gastrointestinal adverse events remain the dominant class-effect liability: in ATTAIN-1, nausea occurred in 33.7% of participants receiving orforglipron 36 mg (investigational capsule dose, equivalent to approved 17.2 mg tablet dose), with adverse-event discontinuation at 10.3%; in ACHIEVE-3, orforglipron produced approximately twice the discontinuation rate of oral semaglutide. The six-step dose-escalation protocol (minimum 30 days per step) is the primary modifiable tolerability variable. Orforglipron undergoes hepatic CYP3A4 metabolism with 87% faecal elimination, introducing hepatic-impairment and drug-interaction liabilities absent for peptides while avoiding renal dose adjustment. Shared class risks include pancreatitis, gallbladder disease, acute kidney injury, and a boxed warning for thyroid C-cell tumour. Conclusion Orforglipron removes injection, cold-chain and fasting requirements, but its gastrointestinal tolerability is not superior to injectable peptides, and gastrointestinal events were more frequent than with oral semaglutide in direct comparison. Findings should not be extrapolated to other oral small molecules, and although cardiovascular non-inferiority to insulin glargine has now been shown (ACHIEVE-4), placebo-controlled outcome trials are required before cardiovascular or renal benefit can be assumed.

doi.org/10.1007/s12020-026-04878-zPubMed 43037879Interventions

AgingResearch.News